# Safety, Tolerability, and Immunogenicity of the Ebola Chimpanzee Adenovirus Vector Vaccine (cAd3-EBO), VRC-EBOADC069-00-VP, in Healthy Adults

> **NCT02231866** · PHASE1 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 143 (actual)

## Conditions studied

- Healthy Adult Immune Responses to Vaccine

## Interventions

- **BIOLOGICAL:** VRC-EBOADC069-00-VP
- **BIOLOGICAL:** VRC-EBOADC076-00-VP

## Key facts

- **NCT ID:** NCT02231866
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-08-27
- **Primary completion:** 2017-04-05
- **Final completion:** 2017-04-05
- **Target enrollment:** 143 (ACTUAL)
- **Last updated:** 2018-07-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02231866

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02231866, "Safety, Tolerability, and Immunogenicity of the Ebola Chimpanzee Adenovirus Vector Vaccine (cAd3-EBO), VRC-EBOADC069-00-VP, in Healthy Adults". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02231866. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*